http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 07:35:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/BriaCell+advances+melanoma+vaccine+candidate+to+genetic+engineering+milestone/26964272.html <p>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that its Bria-MEL+ melanoma immunotherapy vaccine candidate has reached a key genetic engineering milestone, according to a company statement.</p><p>Bria-MEL+ is a whole-cell cancer vaccine designed to activate immune responses against melanoma cells. The program uses premanufactured cell lines selected through patient HLA matching via a saliva test, which the company says removes the need for individualized manufacturing while still enabling patient-specific treatment selection.</p><p>"Bria-MEL+ is designed to combine the advantages of personalized immunotherapy with the accessibility of an off-the-shelf vaccine," said William V. Williams, MD, President and Chief Executive Officer of BriaCell. http://www.streetinsider.com/Corporate+News/BriaCell+advances+melanoma+vaccine+candidate+to+genetic+engineering+milestone/26964272.html Mon, 24 Aug 2026 07:35:40 -0400 BCTX http://www.streetinsider.com/FDA/BriaCell+advances+melanoma+vaccine+candidate+to+genetic+engineering+milestone/26964272.html <p>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that its Bria-MEL+ melanoma immunotherapy vaccine candidate has reached a key genetic engineering milestone, according to a company statement.</p><p>Bria-MEL+ is a whole-cell cancer vaccine designed to activate immune responses against melanoma cells. The program uses premanufactured cell lines selected through patient HLA matching via a saliva test, which the company says removes the need for individualized manufacturing while still enabling patient-specific treatment selection.</p><p>"Bria-MEL+ is designed to combine the advantages of personalized immunotherapy with the accessibility of an off-the-shelf vaccine," said William V. Williams, MD, President and Chief Executive Officer of BriaCell. http://www.streetinsider.com/FDA/BriaCell+advances+melanoma+vaccine+candidate+to+genetic+engineering+milestone/26964272.html Mon, 24 Aug 2026 07:35:40 -0400 BCTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+Jun+26/26698702.html si-local-file:///var/storage/secattach/20260626/26698702.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+Jun+26/26698702.html Fri, 26 Jun 2026 16:06:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+Jun+26/26698702.html si-local-file:///var/storage/secattach/20260626/26698702.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+Jun+26/26698702.html Fri, 26 Jun 2026 16:06:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BriaCell+Therapeutics+++++For%3A+Apr+30/26623652.html si-local-file:///var/storage/secattach/20260609/26623652.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BriaCell+Therapeutics+++++For%3A+Apr+30/26623652.html Tue, 09 Jun 2026 16:06:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BriaCell+Therapeutics+++++For%3A+Apr+30/26623652.html si-local-file:///var/storage/secattach/20260609/26623652.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BriaCell+Therapeutics+++++For%3A+Apr+30/26623652.html Tue, 09 Jun 2026 16:06:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+May+31/26594828.html si-local-file:///var/storage/secattach/20260603/26594828.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+May+31/26594828.html Wed, 03 Jun 2026 06:04:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+May+31/26594828.html si-local-file:///var/storage/secattach/20260603/26594828.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BriaCell+Therapeutics+++++For%3A+May+31/26594828.html Wed, 03 Jun 2026 06:04:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++BriaCell+Therapeutics++++++++++++++++/26587784.html si-local-file:///var/storage/secattach/20260602/26587784.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++BriaCell+Therapeutics++++++++++++++++/26587784.html Tue, 02 Jun 2026 08:00:00 -0400 BCTX O.04468025 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++BriaCell+Therapeutics++++++++++++++++/26587784.html si-local-file:///var/storage/secattach/20260602/26587784.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++BriaCell+Therapeutics++++++++++++++++/26587784.html Tue, 02 Jun 2026 08:00:00 -0400 BCTX O.04468025 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936